SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis - Summary - MDSpire

SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis

A nationwide cohort study found lower rates of cardiorenal complications and hepatic decompensation

  • By

  • Henry Thomas

  • March 10, 2026

  • 2 min

Share

Objective:

To evaluate the association of sodium-glucose cotransporter-2 inhibitors with kidney, cardiovascular, and hepatic outcomes in patients with type 2 diabetes and cirrhosis.

Key Findings:
  • SGLT2 inhibitors associated with lower risk of end-stage kidney disease compared to DPP-4 inhibitors.
  • Reduced risk of acute kidney injury in patients receiving SGLT2 inhibitors.
  • Lower incidence of major adverse cardiovascular events among SGLT2 inhibitor users.
  • Fewer hepatic decompensation events observed in patients on SGLT2 inhibitors.
Interpretation:

SGLT2 inhibitors may offer significant cardiorenal and hepatic benefits for patients with type 2 diabetes and cirrhosis, warranting further prospective studies.

Limitations:
  • Lack of laboratory data on cirrhosis severity in the administrative database.
  • Residual confounding cannot be fully excluded despite statistical adjustments.
Conclusion:

SGLT2 inhibitors demonstrate potential advantages in managing complications associated with type 2 diabetes and cirrhosis, though further research is necessary.

Original Source(s)

SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis

  • by Henry Thomas

  • March 10, 2026

Related Content

Effects of altitude and sociodemographic factors on cardiometabolic disorders in the southwestern plateau areas of China

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.

AD Not Linked to Early CV Risk Markers

Repeated assessments from childhood to early adulthood did not identify consistent cardiometabolic risk patterns by disease activity or severity.